PXS 5338K

Drug Profile

PXS 5338K

Alternative Names: PXS-5338; PXS-5338K

Latest Information Update: 16 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmaxis
  • Developer Pharmaxis; Synairgen
  • Class Antifibrotics; Antineoplastics; Pyrans; Small molecules
  • Mechanism of Action LOXL2 protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Non-alcoholic steatohepatitis
  • Preclinical Hepatic fibrosis; Pulmonary fibrosis; Renal fibrosis
  • No development reported Cancer

Most Recent Events

  • 11 Oct 2018 Pharmacokinetics data from a phase I trial (in volunteers) released by Pharmaxis
  • 13 Aug 2018 PXS 5338K is available for licensing as of 06 Aug 2018 http://www.pharmaxis.com.au;
  • 06 Aug 2018 Preclinical development is ongoing for Renal fibrosis and Pulmonary fibrosis in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top